Methamphetamine-Associated Psychosis

Authors

Kathleen M. Grant, VA Nebraska-Western Iowa Health Care SystemFollow
Tricia D. Le Van, VA Nebraska-Western Iowa Health Care SystemFollow
Sandra M. Wells, University of Nebraska Medical CenterFollow
Ming Li, University of Nebraska-LincolnFollow
Scott F. Stoltenberg, University of Nebraska-LincolnFollow
Howard E. Gendelman, University of Nebraska Medical CenterFollow
Gustavo Carlo, University of Nebraska-LincolnFollow
Rick A. Bevins, University of Nebraska-LincolnFollow

Comments

Published in Journal of Neuroimmune Pharmacology (2012) 7:113–139
DOI 10.1007/s11481-011-9288-1

Abstract

Methamphetamine (METH) is a frequent drug of abuse in U.S. populations and commonly associated with psychosis. This may be a factor in frequent criminal justice referrals and lengthy treatment required by METH users. Persecutory delusions and auditory hallucinations are the most consistent symptoms of METH-associated psychosis (MAP). MAP has largely been studied in Asian populations and risk factors have varied across studies. Duration, frequency and amount of use as well as sexual abuse, family history, other substance use, and co-occurring personality and mood disorders are risk factors for MAP. MAP may be unique with its long duration of psychosis and recurrence without relapse to METH. Seven candidate genes have been identified that may be associated with MAP. Six of these genes are also associated with susceptibility, symptoms, or treatment of schizophrenia and most are linked to glutamatergic neurotransmission. Animal studies of pre-pulse inhibition, attenuation of social interaction, and stereotypy and alterations in locomotion are used to study MAP in rodents. Employing various models, rodent studies have identified neuroanatomical and neurochemical changes associated with METH use. Throughout this review, we identify key gaps in our understanding of MAP and suggest potential directions for future research.